Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/196688
Title: | Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura |
Author: | Pascual Izquierdo, Cristina Mingot Castellano, María Eva Kerguelen Fuentes, Ana E. García Arroba Peinado, José Cid Vidal, Joan Jimenez, Maria Moraima Valcarcel, David Gómez Seguí, Inés Rubia, Javier de la Martin, Paz Goterris, Rosa Hernández, Luis Tallón, Inmaculada Varea, Sara Fernández, Marta García Muñoz, Nadia Vara, Míriam Fernández Zarzoso, Miguel García Candel, Faustino Paciello, María Liz García García, Irene Zalba, Saioa Campuzano, Verónica Gala, José María Vidán Estévez, Julia Moreno Jiménez, Gemma López Lorenzo, José Luis González Arias, Elena Freiría, Carmen Solé, María Ávila Idrovo, Laura Francisca Hernández Castellet, José Carlos Cruz, Naylen Lavilla, Esperanza Pérez Montaña, Albert Atucha, Jon Ander Moreno Beltrán, María Esperanza Moreno Macías, Juán Ramón Salinas, Ramón Rio Garma, Julio del Spanish Apheresis Group (GEA) Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT) |
Keywords: | Rituximab Trombosi Assaigs clínics Rituximab Thrombosis Clinical trials |
Issue Date: | 27-Dec-2022 |
Publisher: | American Society of Hematology |
Abstract: | Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX. |
Note: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2022008028 |
It is part of: | Blood Advances, 2022, vol. 6, num. 24, p. 6219-6227 |
URI: | http://hdl.handle.net/2445/196688 |
Related resource: | https://doi.org/10.1182/bloodadvances.2022008028 |
ISSN: | 2473-9529 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
blooda_adv-2022-008028-main.pdf | 380.72 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License